Replimune, Inc.
Replimune develops oncolytic immunotherapies based on a modified HSV-1 platform designed to induce immunogenic cell death and systemic anti-tumor immune responses.
SCHEDULE 13G/ANov 16Latest SEC filing
Oct 28Latest story
October 2026
August 2026
July 2026
June 2026